- Home
- SOS vs ERNA Comparison
SOS vs ERNA Comparison
Compare SOS & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOS | ERNA |
|---|---|---|
| Founded | 2004 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 10.0M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | SOS | ERNA |
|---|---|---|
| Price | $1.62 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 33.5K | ★ 193.3K |
| Earning Date | 09-26-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $260,505,000.00 | $1,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 134.43 | N/A |
| 52 Week Low | $1.02 | $1.08 |
| 52 Week High | $9.62 | $11.07 |
Technical Indicators
Market Signals| Indicator | SOS | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 46.00 |
| Support Level | $1.58 | $1.14 |
| Resistance Level | $1.82 | $1.28 |
| Average True Range (ATR) | 0.09 | 0.10 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 49.97 | 27.70 |
Price Performance
Historical ComparisonAbout SOS SOS Limited
SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.
About ERNA Eterna Therapeutics Inc.
Ernexa Therapeutics Inc is a biotechnology company. The company develops transformational new medicines using various cell engineering technologies for cancer and autoimmune diseases. The proprietary technology of the company transforms induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs), offering potential off-the-shelf treatment solutions without the need for patient-specific cell harvesting.